Skip to main content
SpringerLink
Log in

Schwerpunkt nichtkleinzelliges Lungenkarzinom

Systemtherapie des metastasierten NSCLC

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

In den letzten Jahren hat sich sehr viel in der Therapie des fortgeschrittenen NSCLC getan. Das liegt vor allem an der Detektion und zielgerichteten Therapie molekularer Aberrationen sowie am Erfolg der Immuntherapie. Dieser Artikel soll Ihnen einen kurzen Überblick darüber geben, wie Patienten mit fortgeschrittenen metastasierten NSCLC aktuell behandelt werden.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Malvezzi M et al. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26(4):779–86

    Article  CAS  PubMed  Google Scholar 

  2. Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50

    Article  CAS  PubMed  Google Scholar 

  3. Scagliotti GV et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51

    Article  CAS  PubMed  Google Scholar 

  4. Schiller JH et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–8

    Article  CAS  PubMed  Google Scholar 

  5. Gazdar AF et al. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010;29(1):37–48

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hirsch FR et al. New and emerging targeted treatments in advanced non-small-cell lung cancer. Lancet. 2016;388(10048):1012–24

    Article  PubMed  Google Scholar 

  7. Shaw AT et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–71

    Article  PubMed  PubMed Central  Google Scholar 

  8. Gainor JF, Shaw AT. Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol. 2013;31(31):3987–96

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gandhi L et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078–92

    Article  CAS  PubMed  Google Scholar 

  10. Gadgeel SM et al. KEYNOTE-189: Updated OS and progression after the next line of therapy (PFS2) with pembrolizumab (pembro) plus chemo with pemetrexed and platinum vs placebo plus chemo for metastatic nonsquamous NSCLC. ASCO. 2019;Abstr. 9013

  11. Socinski MA et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301

    Article  CAS  PubMed  Google Scholar 

  12. Papadimitrakopoulou V et al. IMpower132: PFS and Safety Results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV Non-Squamous NSCLC. J Thorac Oncol. 2019;13(10_Suppl):332–3

    Google Scholar 

  13. West H et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–37

    Article  CAS  PubMed  Google Scholar 

  14. Reck M et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823–33

    Article  CAS  PubMed  Google Scholar 

  15. Paz-Ares L et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040–51

    Article  CAS  PubMed  Google Scholar 

  16. Jotte RM et al. IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. ASCO. 2018;Abstr LBA9000.

  17. Antonia SJ et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342–50

    Article  CAS  PubMed  Google Scholar 

  18. Borghaei H et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(17):1627–39

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Brahmer J et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123–35

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rittmeyer A et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–65

    Article  PubMed  Google Scholar 

  21. Herbst RS et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. LungenClinic Grosshansdorf GmbH, Wöhrendamm 80, 22927, Großhansdorf, Deutschland

    Marlitt Horn (Thoraxonkologischer Schwerpunkt)

Authors
  1. Marlitt Horn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marlitt Horn.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Horn, M. Systemtherapie des metastasierten NSCLC. Info Onkol. 22, 24–29 (2019). https://doi.org/10.1007/s15004-019-6648-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-6648-0

Search

Navigation